A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Latest Information Update: 03 Mar 2022
At a glance
- Drugs GLWL 01 (Primary)
- Indications Prader-Willi syndrome
- Focus Therapeutic Use
- Sponsors GLWL Research
- 25 Feb 2022 Results published in the Journal of Clinical Endocrinology and Metabolism
- 17 Jun 2019 Status changed from active, no longer recruiting to completed.
- 25 Feb 2019 Status changed from recruiting to active, no longer recruiting.